HPBPE002.1

HPBPE002.1 is an exosome-based therapy developed by AM Biotech using its proprietary Biochemical Pulse Exosome Drug Development Platform. It is currently in preclinical development for the treatment of premature ovarian failure, menopausal symptoms, and intimate area care. The therapy utilizes exosomes, which are extracellular vesicles that facilitate intercellular communication by transferring proteins, lipids, and nucleic acids to target cells. While the specific molecular targets are not disclosed, the therapy aims to leverage the regenerative and signaling properties of exosomes to address gynecological and reproductive health conditions.

Other names

HPBPE002.1-AM Biotech-exosome therapy-Premature Ovarian Failure-Menopausal Symptoms-Intimate Area CareHPBPE-002.1-AM Biotech-exosome therapy-Premature Ovarian Failure-Menopausal Symptoms-Intimate Area CareHPBPE 002.1-AM Biotech-exosome therapy-Premature Ovarian Failure-Menopausal Symptoms-Intimate Area Care